^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Truxima (rituximab-abbs) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with:...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Source:
Title:
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
Excerpt:
...Patient has relapsed or refractory CD20-positive disease following previous first-line systemic chemotherapy....
Trial ID:
Source:
Title:
1125 Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma
Published date:
11/04/2020
Excerpt:
Over the study period, 115 (88%; CT-P10) and 111 (87%; rituximab) patients achieved overall response. At a median follow-up of 29·2 months (IQR: 26·1–33·7), median progression-free survival, time-to-progression, and overall survival were not estimable. The KM estimates (95% CI) for OS at 36 months were 98% (93–99) and 97% (89–99) in the CT-P10 and rituximab groups, respectively. Corresponding values for PFS were 80% (70–87) and 68% (54–79), while results for TTP were 82% (72–88) and 68% (54–79) in the CT-P10 and rituximab groups, respectively.
